Pharmafile Logo

dual tasking

Biogen Idec building

Biogen discontinues clinical development of anti-tau antibody for Alzheimer’s disease

The drug failed to meet the primary efficacy endpoint in a phase 2 study

- PMLiVE

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

- PMLiVE

Ashfield Advisory adds Mary-Kate McGarry and Emer Jameson to senior leadership team

McGarry has been appointed as vice president of strategy, while Jameson joins as vice president of HR

- PMLiVE

Servier, Oncodesign select first preclinical candidate from Parkinson’s disease collaboration

Oncodesign received the first milestone payment in February 2020 as part of the collaboration

- PMLiVE

GSK partners with iTeos Therapeutics on next-gen immuno-oncology drug

British drug-maker will pay $625m upfront for access to iTeos' anti-TIGIT monoclonal antibody

- PMLiVE

Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses

Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Top 10 ways that Medical Affairs teams can leverage the Impetus InSite Platform®

Some of the most popular and innovative ways of using our cutting-edge asynchronous and synchronous virtual tools for Medical Affairs teams.

Impetus Digital

- PMLiVE

Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3

Biogen and Sage signed a $3.1bn deal last year to jointly develop potential depression therapies

The power of communication: Engaging diverse groups in healthcare

Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...

Page & Page Health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links